ADAs to Alemtuzumab - Trial NCT06310343
Access comprehensive clinical trial information for NCT06310343 through Pure Global AI's free database. This phase not specified trial is sponsored by Queen Mary University of London and is currently Recruitment Completed. The study focuses on Multiple Sclerosis. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Queen Mary University of London
Timeline & Enrollment
N/A
Apr 25, 2022
Nov 30, 2025
Primary Outcome
To quantify the longitudinal changes in alemtuzumab ADAs
Summary
The main aim is to quantify the changes in alemtuzumab antibody-anti-alemtuzumab over a 24
 months period
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06310343
Non-Device Trial